Premium
A new application for liposomes in cancer therapy
Author(s) -
Vingerhoeds M.H.,
Haisma H.J.,
van Muijen M.,
van de Rijt R.B.J.,
Crommelin D.J.A.,
Storm G.
Publication year - 1993
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/0014-5793(93)80861-n
Subject(s) - prodrug , liposome , cytotoxicity , epirubicin , chemistry , enzyme , in vitro , ovarian cancer , pharmacology , adept , cancer cell , cancer therapy , cancer , biochemistry , cancer research , medicine , breast cancer
We have tested a new type of immunoliposomes which may effectively mediate the targeting of enzymes to be used for site‐specific prodrug activation (immuno‐enzymosomes). The enzyme β‐glucuronidase, capable of activating the prodrug epirubicin‐glucuronide (epi‐glu), was coupled to the external surface of immunoliposomes directed towards ovarian cancer cells. A significant increase in cytotoxicity of the prodrug epi‐glu was shown when the in vitro cultured cancer cells were pretreated with these immuno‐enzymosomes.